SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and rising volume have drawn attention, with traders linking the move to Starknets privacy and Bitcoin-DeFi initiatives and its post-quantum security narrative. Sentiment is broadly bullish on momentum and the projects technology, though some traders question whether gains can hold amid token-unlock and dilution concerns.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives proposed supply-squeeze update, which traders say could double INJs deflation rate if approved, is fueling bullish discussion alongside progress in tokenization and institutional finance. Optimists point to burns, staking and ecosystem growth, while skeptics remain wary of the tokens prolonged decline and question whether those developments will translate into sustained demand.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

Bitdeers AI/HPC expansion is drawing attention, particularly its announced long-term Norway data-center lease, while the companys at-the-market share offering has fueled concerns about dilution amid weak price action. Bulls point to the AI infrastructure opportunity alongside Bitcoin mining, while skeptics question whether the growth will translate into shareholder gains.

Alignment Healthcare, Inc. is a holding company, which offers a consumer-centric platform that delivers customized health care solutions to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. It offers health plan options through Alignment Health Plan, and partners with select health plans to help deliver better benefits at lower costs. The company was founded by John E. Kao in 2013 and is headquartered in Orange, CA.

Alignment Healthcare Inc

Alignment Healthcares largest California Medicare Advantage contract fell from four to 3.5 stars, putting its eligibility for quality bonus payments at risk and driving a sharp selloff. Traders debate how much this could weigh on future earnings, with some expecting the company to challenge the rating and others viewing the potential 2028 impact as substantial.

Wachovia Corporation, a financial holding company, provides commercial and retail banking services, and other financial services. Wachovia was a diversified financial services company based in Charlotte, North Carolina. Before its acquisition by Wells Fargo in 2008, Wachovia was the fourth-largest bank holding company in the United States based on total assets. Wachovia provided a broad range of banking, asset management, wealth management, and corporate and investment banking products and services. At its height, it was one of the largest providers of financial services in the United States, operating financial centers in 21 states and Washington, D.C., with locations from Connecticut to Florida and west to California.

Wells Fargo & Co.

Wells Fargo is drawing attention ahead of its Q3 earnings as bank shares face pressure from rising Treasury yields and concerns about margins and deposit costs. Traders are split between buying the pullbackciting Wells Fargos Morgan Stanley upgrade and improving prospects after the asset-cap removaland waiting for earnings to clarify the outlook.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT traders are weighing a rebound against lingering concerns from the Wanchain bridge exploit and ongoing airdrop/unlock-related selling. Bulls point to the mainnet rollout, validator and partnership developments, and reported Coinbase availability as signs of adoption, while skeptics remain cautious about supply pressure and the exploits impact on confidence.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention for a technical rebound, with traders watching a break above resistance near $26$27 and citing bullish chart patterns. Many are optimistic about its capped token supply and planned V4 and institutional-market expansion, while others remain frustrated by uneven price action; the breakout thesis is speculative.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is drawing attention amid a sharp pullback across uranium and nuclear stocks, with traders divided over whether the shares are forming a bottom or facing further pressure as enthusiasm for the nuclear theme cools. Cigar Lakes temporary production suspension added supply concerns, though Cameco said operations resumed and its production outlook was unchanged; bulls continue to cite long-term nuclear demand and Westinghouse exposure.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

Hyperliquids buyback-and-burn program, funded by protocol revenue, is a major focus as traders react to HYPEs rally and fresh highs. Bulls see recurring buybacks and growing platform activity as supportive, while others point to token unlocks, profit-taking, and pullback risk.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

Bitcoins rebound and traders view that it may have bottomed are fueling bullish interest in MSTX, a 2x leveraged MSTR ETF. Some traders remain cautious about its volatility and leverage decay, with bearish options activity viewed by some as hedging rather than a directional bet.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayPR NewswireTEL AVIV, Israel...

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a...

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 31, 2026 - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third...

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PR Newswire TEL AVIV, Israel, Aug. 28, 2026 TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PR Newswire TEL AVIV, Israel, Aug. 25, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO...

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and...

BioLineRx (BLRX) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO...

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Bioline Rx Ltd - ADR

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.22
Prev Close	$2.21
Open	$2.20
Dividend Yield	0.00%
50-Day Moving Average	$2.60
Beta	0.93
Avg. Volume	18,543.36
PE Ratio	-1.22

52-Week High	$4.15
52-Week Low	$2.15
Market Capitalization	$11.03M
EPS (Annual)	-$0.2903
Price to Book	0.70
Revenue Per Employee	$49,556.71

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLRX Fundamentals